B-cell proliferation characteristics and monitoring significance under the modified reduced-dose rituximab regimen for NMOSD: A real-world case series study

Annovazzi, 2016, Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study, J. Neurol., 263, 1727, 10.1007/s00415-016-8188-y Bennett, 2015, B lymphocytes in neuromyelitis optica, Neurol. Neuroimmunol. Neuroinflamm., 2, e104, 10.1212/NXI.0000000000000104 Cabre, 2018, Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study, J. Neurol., 265, 917, 10.1007/s00415-018-8771-5 Cao, 2021, Efficacy and safety of modified reduced-dose rituximab in Chinese patients with neuromyelitis optica spectrum disorder: a retrospective cohort study, J. Neurol. Sci., 429, 10.1016/j.jns.2021.117616 Chan, 2011, Brain involvement in neuromyelitis optica spectrum disorders, Arch. Neurol., 68, 1432, 10.1001/archneurol.2011.249 Chay, 2013, Experience with low-dose rituximab in off-label indications at two tertiary hospitals, Intern. Med. J., 43, 871, 10.1111/imj.12207 Ciron, 2018, Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders, Rev. Neurol. (Paris), 174, 255, 10.1016/j.neurol.2017.11.005 Cohen, 2017, Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: results from a bicentric study, J. Neurol. Sci., 373, 335, 10.1016/j.jns.2017.01.025 Collongues, 2016, An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica, Ther. Adv. Neurol. Disord., 9, 180, 10.1177/1756285616632653 Cree, 2005, An open label study of the effects of rituximab in neuromyelitis optica, Neurology, 64, 1270, 10.1212/01.WNL.0000159399.81861.D5 Damato, 2016, Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis, JAMA Neurol., 73, 1342, 10.1001/jamaneurol.2016.1637 Dass, 2008, Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis, Arthritis Rheum., 58, 2993, 10.1002/art.23902 Ellrichmann, 2019, Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders, J. Neurol., 266, 57, 10.1007/s00415-018-9092-4 Ellwardt, 2018, Monitoring B-cell repopulation after depletion therapy in neurologic patients, Neurol. Neuroimmunol. Neuroinflamm., 5, e463, 10.1212/NXI.0000000000000463 Fujihara, 2019, Neuromyelitis optica spectrum disorders: still evolving and broadening, Curr. Opin. Neurol., 32, 385, 10.1097/WCO.0000000000000694 Greenberg, 2012, Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success, Mult. Scler., 18, 1022, 10.1177/1352458511432896 Jacob, 2008, Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients, Arch. Neurol., 65, 1443, 10.1001/archneur.65.11.noc80069 Jeong, 2016, Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints, Mult. Scler., 22, 329, 10.1177/1352458515587752 Kim, 2013, A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder, JAMA Neurol., 70, 1110, 10.1001/jamaneurol.2013.3071 Kim, 2015, Anti-JC virus antibodies in rituximab-treated patients with neuromyelitis optica spectrum disorder, J. Neurol., 262, 696, 10.1007/s00415-014-7629-8 Kim, 2019, Individualized B cell-targeting therapy for neuromyelitis optica spectrum disorder, Neurochem. Int., 130, 10.1016/j.neuint.2018.11.022 Kim, 2015, Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab, JAMA Neurol., 72, 989, 10.1001/jamaneurol.2015.1276 Kim, 2011, Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years, Arch. Neurol., 68, 1412, 10.1001/archneurol.2011.154 Kim, 2019, Less frequent rituximab retreatment maintains remission of neuromyelitis optica spectrum disorder, following long-term rituximab treatment, J. Neurol. Neurosurg. Psychiatry, 90, 486, 10.1136/jnnp-2018-318465 Lebrun, 2018, Only follow-up of memory B cells helps monitor rituximab administration to patients with neuromyelitis optica spectrum disorders, Neurol. Ther., 7, 373, 10.1007/s40120-018-0101-4 Lennon, 2004, A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis, Lancet, 364, 2106, 10.1016/S0140-6736(04)17551-X Lin, 2018, Low-dosage of rituximab in Chinese patients with neuromyelitis optica spectrum disorder, J. Neuroimmunol., 317, 1, 10.1016/j.jneuroim.2018.02.004 Lindsey, 2012, Variable results after rituximab in neuromyelitis optica, J. Neurol. Sci., 317, 103, 10.1016/j.jns.2012.02.017 Lu, 2020, A long-term follow-up of rituximab treatment in 20 Chinese patients with neuromyelitis optica spectrum disorders, Mult. Scler. Relat. Disord., 40, 10.1016/j.msard.2020.101933 Mealy, 2014, Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy, JAMA Neurol., 71, 324, 10.1001/jamaneurol.2013.5699 Mirmosayyeb, 2021, Efficacy and safety of rituximab in treating patients with Neuromyelitis optica spectrum disorder (NMOSD): a systematic review and meta-analysis, Autoimmun. Rev., 20, 10.1016/j.autrev.2020.102727 Mitsdoerffer, 2013, Immunology of neuromyelitis optica: a T cell-B cell collaboration, Ann. N. Y. Acad. Sci., 1283, 57, 10.1111/nyas.12118 2016, Chinese guidelines for diagnosis and treatment of neuromyelitis optica spectrum disorder (2016 edition), Chin. J. Neuroimmunol. Neurol., 23, 155 Novi, 2019, Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders, Mult. Scler. Relat. Disord., 36, 10.1016/j.msard.2019.101430 Pellkofer, 2011, Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab, Neurology, 76, 1310, 10.1212/WNL.0b013e3182152881 Poupart, 2020, Evaluation of efficacy and tolerability of first-line therapies in NMOSD, Neurology, 94, e1645, 10.1212/WNL.0000000000009245 Radaelli, 2016, Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients, Mult. Scler., 22, 511, 10.1177/1352458515594042 Torres, 2015, Analysis of the treatment of neuromyelitis optica, J. Neurol. Sci., 351, 31, 10.1016/j.jns.2015.02.012 van Vollenhoven, 2015, Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 Years, J. Rheumatol., 42, 1761, 10.3899/jrheum.150051 Wingerchuk, 2015, International consensus diagnostic criteria for neuromyelitis optica spectrum disorders, Neurology, 85, 177, 10.1212/WNL.0000000000001729 Xiao, 2020, Retrospective observation of low-dose rituximab treatment in Chinese patients with neuromyelitis optica spectrum disorders in a real-world setting, Front. Neurol., 11, 642, 10.3389/fneur.2020.00642 Yang, 2013, Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica, Neurology, 81, 710, 10.1212/WNL.0b013e3182a1aac7 Yang, 2018, Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder, J. Neurol. Sci., 385, 192, 10.1016/j.jns.2017.12.034 Yu, 2019, Efficacy and safety of reduced-dose rituximab in the treatment of optic neuromyelitis optica spectrum disease, Chin. J. Clin. Neurosci., 27, 309 Zhang, 2017, Effectiveness of low dose of rituximab compared with azathioprine in Chinese patients with neuromyelitis optica: an over 2-year follow-up study, Acta Neurol. Belg., 117, 695, 10.1007/s13760-017-0795-6